Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Current Drug Metabolism

Advances in Controlled Release Formulations for Ocular Diseases: Improving Patient Compliance and Therapeutic Outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

SNSmita NarwalAvantha Centre for Industrial Research & DevelopmentDDushyantKurukshetra UniversityGSGurvirender SinghKurukshetra University

Discussion

Loading...

Member takes

Implication

Review reports on new formulations and delivery methods for ocular diseases, highlighting improvements in bioavailability and patient compliance.

Key Points

  • Innovative formulations significantly improve ocular bioavailability, enhancing treatment efficacy for various eye conditions.
  • Nanotechnology offers advanced carriers that increase drug stability and ocular permeability, leading to better therapeutic outcomes.
  • Evaluation includes hydrogels, microneedles, and other novel delivery techniques addressing physiological barriers in ocular therapies.
  • Study reveals challenges in ocular drug delivery and the need for innovative solutions to improve patient compliance and treatment effectiveness.

Cite This Study

Narwal et al. (2025) studied this question.

synapsesocial.com/papers/68bb49c46d6d5674bccff9d4https://doi.org/10.2174/0113892002384586250731104453
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists2022 · 188 citations
  2. 2Efficacy of Tacrolimus in Uveitis, and the Usefulness of Serum Tacrolimus Levels in Predicting Disease Control. Results from a Single Large Center2021 · 12 citations
  3. 3Obstruction and Approaches to Cross the Drug Molecules through Blood Retinal Barrier: An Overview2024 · 3 citations
  4. 4Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate2022 · 54 citations